COLL Insider Trading

Insider Ownership Percentage: 2.51%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $7,872,884.47

Collegium Pharmaceutical Insider Trading History Chart

This chart shows the insider buying and selling history at Collegium Pharmaceutical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$2M$0$2MTotal Insider BuyingTotal Insider Selling

Collegium Pharmaceutical Share Price & Price History

Current Price: $26.91
Price Change: Price Decrease of -0.1 (-0.37%)
As of 04/21/2025 05:00 PM ET

This chart shows the closing price history over time for COLL up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$26.91Closing price on 04/21/25:

SEC Filings (Institutional Ownership Changes) for Collegium Pharmaceutical (NASDAQ:COLL)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at COLL by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$995kbought$1.86MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50M$0$50MTotal InflowsTotal Outflows
Collegium Pharmaceutical logo
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Read More on Collegium Pharmaceutical

Today's Range

Now: $26.91
Low: $26.48
High: $27.61

50 Day Range

MA: $28.67
Low: $24.67
High: $30.98

52 Week Range

Now: $26.91
Low: $23.23
High: $42.29

Volume

351,732 shs

Average Volume

443,006 shs

Market Capitalization

$864.67 million

P/E Ratio

11.60

Dividend Yield

N/A

Beta

0.76

Who are the company insiders with the largest holdings of Collegium Pharmaceutical?

Collegium Pharmaceutical's top insider investors include:
  1. Joseph Ciaffoni (CEO)
  2. Colleen Tupper (CFO)
  3. Shirley R Kuhlmann (EVP)
  4. Scott Dreyer (EVP)
  5. Thomas B Smith (EVP)
  6. Garen G Bohlin (Director)
Learn More about top insider investors at Collegium Pharmaceutical.

Who are the major institutional investors of Collegium Pharmaceutical?

Collegium Pharmaceutical's top institutional investors include:
  1. Rhumbline Advisers — 0.35%
  2. Assenagon Asset Management S.A. — 0.32%
  3. Exchange Traded Concepts LLC — 0.19%
  4. Ritholtz Wealth Management — 0.10%
  5. SummerHaven Investment Management LLC — 0.08%
  6. Harbor Capital Advisors Inc. — 0.06%
Learn More about top institutional investors of Collegium Pharmaceutical stock.

Which institutional investors are selling Collegium Pharmaceutical stock?

In the previous quarter, COLL stock was sold by these institutional investors:
  1. Assenagon Asset Management S.A.
  2. Exchange Traded Concepts LLC
  3. Harbor Capital Advisors Inc.
  4. Ritholtz Wealth Management
  5. State of Alaska Department of Revenue
During the last year, company insiders that have sold Collegium Pharmaceutical company stock include:
  1. Joseph Ciaffoni (CEO)
  2. Colleen Tupper (CFO)
  3. Shirley R Kuhlmann (EVP)
  4. Scott Dreyer (EVP)
  5. Thomas B Smith (EVP)
Learn More investors selling Collegium Pharmaceutical stock.

Which institutional investors are buying Collegium Pharmaceutical stock?

Within the previous quarter, COLL stock was acquired by institutional investors including:
  1. GAMMA Investing LLC
  2. Janney Montgomery Scott LLC
  3. Rhumbline Advisers
  4. SG Americas Securities LLC
  5. Farther Finance Advisors LLC
  6. SummerHaven Investment Management LLC